Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Custom Recombinant Protein Production Services Market, By Expression System (Mammalian, Bacteria, Insect, Yeast, and Others), By End User (Research Institutes, Biotechnology and  Pharmaceutical Companies, Contract Research Organizations and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 3,958.0 Mn in 2021 and is expected to exhibit a CAGR of 11.4% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Rising funding and investment activities in the field of biotechnology are expected to drive growth of the custom recombinant protein production services market over the forecast period. For instance, in November 2019, Bio-Techne committed to invest between US$ 40 million to 50 million to expand protein production capacity of GMP-grade. This investment funded a new facility dedicated to support the GMP-grade material production on a large scale, which included recombinant proteins derived from E. coli. Recombinant proteins are an essential component for several cell therapy manufacturing and bioprocessing workflows.

Custom Recombinant Protein Production Services Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic has drastically affected the research and development activities across the globe. Capacity of lab is reduced due to disruptions are observed in product development for adjustment in remote work environments. Clinical trials are also affected severely with disruptions in keeping the existing patients on therapies and in carrying out new enrolments. According to the clinicaltrial.gov, as of April 2020, there were over 2,850 ongoing trials and around 900,000 patients were enrolled in regions that were in partial or complete lockdown due to COVID-19 restrictions at the trial sites. Several R&D labs are operating at below 50% of normal capacity.

Browse Market Data 26 Tables and 30 Figures spread through 207 Pages and in-depth TOC on “Custom Recombinant Protein Production Services Market,”- Forecast to 2028, Custom Recombinant Protein Production Services Market, By Expression System (Mammalian, Bacteria, Insect, Yeast, and Others), By End User (Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Research Organizations and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Custom Recombinant Protein Production Services Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/custom-recombinant-protein-production-services-market-2737

Moreover, increasing research and development in the field of life sciences is also expected to aid in growth of the custom recombinant protein production services market over the forecast period. For instance, in October 2020, a leading global manufacturing and contract development organization (CDMO) for biopharmaceuticals called ATUM, and Rentschler Biopharma SE a Contract Development and Manufacturing Organization (CDMO) focused on the development and manufacturing of biopharmaceuticals, signed a full license agreement for the Leap-in transposase platform. The Leap-In Transposase platform is a bioengineered solution for the efficient, fast, robust, and stable expression of recombinant proteins in mammalian cells.

Key Takeaways of the Custom Recombinant Protein Production Services Market:

  • Custom recombinant protein production services market is predicted to have CAGR of 11.4% during the forecast period due to rising acquisition activities by companies in life sciences sector, this is expected to boost growth of the market. For instance, on July 14, 2021, Curia, a leading manufacturing and development contract research organization, announced that they had entered into an agreement for acquisition of LakePharma Inc.
  • Among expression system, the mammalian segment is observed to have highest market share in the market over the forecast period, owing to the growing research and development in the field of life sciences. Various expression systems are used for producing the specific recombinant proteins. Mammalian expression system can be used to yield proteins temporarily or through stable cell lines where the expression construct is incorporated into the host genome.
  • On the basis of end user, biotechnology and pharmaceutical companies segment accounts for the largest market share in the custom recombinant protein production services market over the forecast period. Increasing number of funding and investment undertaken by biotech and pharma companies is expected to propel the growth of the segment. For instance, according to Pharmaceutical Research and Manufacturers of America (PhRMA)’s 2016 report, member companies invested an estimated US$ 58.8 billion in research and development in 2015, which constituted the majority spending of all biopharmaceutical R&D in the U.S.
  • On the basis of region, North America segment account higher market share in custom recombinant protein production services market over the forecast period. Most of the recombinant protein manufacturers are based in the U.S. which is a major factor driving growth of the market in North America region. For instance, Crown Bioscience, Inc., BPS Bioscience, Inc., and Novoprotein Scientific based in the U.S. provide custom recombinant protein production services for applications in various segments.
  • Major players operating in the custom recombinant protein production services market are GenScript Biotech Corporation, SignalChem Biotech Inc., Crown Bioscience, Inc., BPS Bioscience Inc., Novoprotein, Applied Biological Materials (abm) Inc., Eurofins Pharma Discovery Services, Abgent (WuXi AppTec Company), OriGene Technologies, Inc., Kempbio, Inc., Trenzyme GmbH, Sino Biological Inc., Aragen Bioscience, a GVKBIO Company, and LakePharma, Inc., Proteos Inc., Icosagen AS, Novus Biological LLC, ProteoGenix, Premas Biotech, ATUM, and Aldevron
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.